Compare MTW & OCGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTW | OCGN |
|---|---|---|
| Founded | 1902 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 498.8M | 419.8M |
| IPO Year | 1994 | 2014 |
| Metric | MTW | OCGN |
|---|---|---|
| Price | $13.56 | $1.30 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $10.50 | $9.75 |
| AVG Volume (30 Days) | 263.8K | ★ 9.4M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.58 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,240,900,000.00 | N/A |
| Revenue This Year | $4.73 | N/A |
| Revenue Next Year | $2.98 | $1,718.38 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.89 | N/A |
| 52 Week Low | $9.09 | $0.93 |
| 52 Week High | $15.56 | $2.73 |
| Indicator | MTW | OCGN |
|---|---|---|
| Relative Strength Index (RSI) | 57.63 | 39.97 |
| Support Level | $12.23 | $1.30 |
| Resistance Level | $14.40 | $1.58 |
| Average True Range (ATR) | 0.50 | 0.07 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 99.35 | 14.71 |
Manitowoc Co Inc provides engineered lifting solutions. It designs and manufactures mobile telescopic cranes, tower cranes, lattice-boom crawler cranes, and boom trucks. It offers products under brand names such as Grove, Manitowoc, National Crane, Potain, Shuttlelift, and Manitowoc Crane Care. Its crane products serve dealers, rental companies, contractors, and government entities in diverse markets, including energy production/distribution and utility, petrochemical and industrial, infrastructure, and commercial/residential construction. Manitowoc has three reportable segments: the Americas, Europe and Africa, and the Middle East and Asia-Pacific. The Americas segment generates the majority of the revenue for the company.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").